Contracts & Pricing May 22, 2022 CMS Medicaid Copay Ruling 4 Minute Read And other industry updates including the Medi-Cal older adult expansion and profiles of new pharmacy models and 3PLs entering the market.
Contracts & Pricing April 28, 2022 Regulatory Market Updates, April 2022 3 Minute Read We recap pressing issues from the past month, including the DUNS number transition, the latest in the Eli Lilly/Streck case, and rising healthcare spending for U.S. payers.
Market Access Blogs April 19, 2022 The Top 10 Market Access Challenges 5 Minute Read We explore the 10 most common challenges facing Market Access operations, based on over 15 years of experience with more than 250 pharma manufacturers.
Contracts & Pricing April 11, 2022 Best Price and Copay Challenges: Frequently Asked Questions 11 Minute Read Common manufacturer concerns on best price calculations, copay accumulators and maximizers, and 340B management as the effective date for the CMS Final Rule approaches.
Contracts & Pricing March 28, 2022 Medicare Part B Sequestration Update 3 Minute Read Regulatory Market Update Updates for Pharma Manufacturers As always, if you have questions on any of the content found in this or previous market updates, please reach out to...
Launch Readiness March 24, 2022 Best Practices: Achieving Your Pre-Launch Sales Forecasts 6 Minute Read Market access leaders from DBV Technologies, Karyopharm Therapeutics, and Sesen Bio discuss critical factors in a successful launch and ways to achieve pre-launch forecasts.
ICyte Platform March 7, 2022 Unifying IntegriChain’s Services & Support: Customer Support and Value Realization 4 Minute Read In his second unification-focused blog, President and COO Josh Halpern discusses IntegriChain's investment in customer support to better augment the value for customers and end-users.
Market Access Blogs February 28, 2022 Overcoming Drug Commercialization Challenges in Rare Disease 5 Minute Read Solutions to common challenges that manufacturers face when commercializing rare and orphan disease therapies.
Contracts & Pricing February 24, 2022 Branded Pharma Fee: Manufacturer Considerations 5 Minute Read And other regulatory updates on Line Extension guidance, the upcoming DUNS number transition, and emergency 340B flexibilities.
